Ansari J, Chehrei A, Amini M, Alizade S H, Sanei M H
Dept. of Radiation Oncology, Aiatollah Khoansari Hospital, Arak University of Medical Sciences, Arak, Iran.
Dept. of Pathology, Amiralmoamenin Hospital, Arak University of Medical Sciences, Arak, Iran.
Iran J Cancer Prev. 2011 Fall;4(4):170-6.
Her2/neu is one of the epidermal growth factor receptors families and seems to have prognostic significance of some solid tumors. The objective of this study is to evaluate the possibility of Her2 expression in gastric cancers and the possible relationship of Her2 with tumor's clinicopathologic parameters and also its prognostic role.
This study was performed on 100 cases of gastric carcinoma with stage I b to III (according to TNM staging). Survival, recurrence date of patients, grade and lymph nodes involvement were assessed. Her2/neu expression was determined by immunohistochemical method on received sample blocks. Survival of patients with or without Her2-neu expression were evaluated by Kaplan- Meier method and compared with the log-rank test followed by multivariate analysis using Cox regression.
Seven cases were 3+ membranous Her2 reactivity, 5 cases were 2+ and13 cases were 1+; also 75% of cases demonstrated no reactivity. Regardingrelationship between tumor grade and membranous Her2 , all patients with poorly differentiated tumors were Her2 negative but patients with moderate and well differentiated tumor had 18.1% and 19.6% Her2 reactivity respectively; there were no significant difference between groups statistically(P>0.05). Median overall survival was 27.25 and 46 months in Her2 negative and her2 positive cases respectively; there were no significant difference between groups statistically as well (P>0.05).
Her2 reactivity has not relationship with tumor grade and lymph node involvement as well as tumor stage. From the other point of view no significant correlation is found between Her2 expression and disease free survival or overall survival of gastric cancer patients.
Her2/neu是表皮生长因子受体家族之一,似乎对某些实体瘤具有预后意义。本研究的目的是评估Her2在胃癌中的表达可能性,以及Her2与肿瘤临床病理参数之间的可能关系及其预后作用。
本研究对100例I b期至III期(根据TNM分期)的胃癌患者进行。评估患者的生存率、复发日期、分级和淋巴结受累情况。通过免疫组织化学方法在收到的样本块上测定Her2/neu的表达。采用Kaplan-Meier法评估有或无Her2-neu表达患者的生存率,并通过对数秩检验进行比较,随后使用Cox回归进行多变量分析。
7例为膜性Her2反应性3+,5例为2+,13例为1+;此外,75%的病例无反应性。关于肿瘤分级与膜性Her2之间的关系,所有低分化肿瘤患者的Her2均为阴性,但中分化和高分化肿瘤患者的Her2反应性分别为18.1%和19.6%;两组之间在统计学上无显著差异(P>0.05)。Her2阴性和Her2阳性病例的中位总生存期分别为27.25个月和46个月;两组之间在统计学上也无显著差异(P>0.05)。
Her2反应性与肿瘤分级、淋巴结受累以及肿瘤分期均无关。从另一方面来看,未发现Her2表达与胃癌患者的无病生存期或总生存期之间存在显著相关性。